Quanterix Corporation, the single molecule diagnostics company focused on developing and commercializing high sensitivity tests, announced the publication of a breakthrough study of the company's proprietary technology that demonstrates an unprecedented sensitivity for measuring a biomarker for prostate cancer recurrence. The research article, featured on the cover of the June issue (Volume 28, No. 6) of Nature Biotechnology, describes how researchers developed a simple blood test using Quanterix's Single Molecule Array (SiMoA™) technology to selectively capture and measure individual Prostate Specific Antigen (PSA) molecules in prostate cancer patients. The study showed that SiMoA was 1,700 times more sensitive than standard hospital tests, potentially allowing for detection of prostate cancer recurrence years earlier than current tests.
Read more at Medical News Today.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment